Approval of Alteration in Object Clause of the Memorandum of Association ("MOA") of the Company

Date: 21st August, 2026 BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 544409 ISIN: INE0TG901011 Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Alteration in the Object Clause of the Memorandum of Association of Astonea Labs Limited Dear Sir/Madam, Pursuant to Regulation 30 read with the applicable provisions of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we wish to inform you that the Members of Astonea Labs Limited (“the Company”), at their 9th Annual General Meeting (“AGM”) held on Friday, 21 August 2026 at 11:30 A.M. at Mercure Hotel, Plot No. 51, Near Tribune Chowk, Industrial Area Phase II, Chandigarh- 160002, considered and approved, by way of a Special Resolution, the alteration in the Object Clause of the Memorandum of Association (“MOA”) of the Company. The alteration has been approved pursuant to Section 13 and other applicable provisions of the Companies Act, 2013. The aforesaid alteration is intended to suitably expand and align the objects of the Company with its proposed and existing business activities, including manufacturing, processing, marketing, distribution and sale of pharmaceutical, nutraceutical, healthcare, ayurvedic and allied products, as well as undertaking lawful commercial channels including retail, wholesale, institutional sales, franchise arrangements, e-commerce platforms and digital marketplaces. We respectfully request that the Exchange be pleased to take cognizance of the aforesaid submission for its information and records. Thanking you. Yours faithfully, For ASTONEA LABS LIMITED ANKIT KAPOOR COMPANY SECRETARY & COMPLIANCE OFFICER M.NO. A75702 Encl.: Annexure - A GSTIN NO.: 06AAPCA4446E1ZP I CIN: L24304CH2017PLC041482 (Formely known as Astonea Labs Private Limited) Reg.Off: SCO 321-322, Basement, Sector 35B, Chandigarh, India-160022 Corporate Office: 63, Industrial Area, Phase II, Panchkula, Haryana, India-134113 Plant: Village Haripur, Teh. Raipur Rani, Distt., Panchkula, India-134204 Mobile No.:+91 7888 491 385, Email: info@astonea.org, Website: https://astonea.org/ ANNEXURE - A Brief Details of Alteration in the Object Clause of the Memorandum of Association Pursuant to Regulation 30 read with the applicable provisions of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, and the applicable provisions of the SEBI Master Circular dated 30 January 2026 for compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 by listed entities, the brief details of the alteration in the Memorandum of Association of Astonea Labs Limited are as follows: S.No. Particulars Details 1. Nature of Amendment Alteration in the Object Clause of the Memorandum of Association 2. Clause Altered Clause III(A) - Main Objects 3. Type of Approval Special Resolution 4. Date of Shareholders’ 21st August, 2026 Approval 5. Mode of Approval At the 9th Annual General Meeting of the Company 6. Reason / Purpose of To expand and align the objects of the Company with its existing Amendment and proposed business activities in the pharmaceutical, nutraceutical, healthcare, ayurvedic and allied sectors and to facilitate wider lawful modes of marketing, distribution and sale of its products. Details of the Alteration: The existing Clause III(A) of the Memorandum of Association has been altered by substituting/adding the following objects: 1. To manufacture, formulate, process, develop, refine, import, export, buy, sell, distribute, market, wholesale and/or retail trade, act as agents, stockists, franchisees or otherwise deal in all kinds of pharmaceuticals, antibiotics, drugs, medicines, biologicals, nutraceuticals, healthcare products, ayurvedic products, dietary supplements, medicinal preparations, vaccines, chemicals, chemical products, dry salters, mineral waters, soups, and other restoratives or foods and to manufacture, process, vial, bottle, pack, repack, label, relabel, store and deal in tablets, capsules, syrups, injections, ointments and other pharmaceutical formulations, and to carry on the business of druggists, distributors, dealers, buyers, sellers, importers, exporters and stockists of all kinds of pharmaceuticals and allied products. The Company may also manufacture, process and deal in medicinal and allied goods including surgical instruments, contraceptives, photographic goods, oils, perfumes, cosmetics, patent and proprietary medicines, soaps, artificial limbs, hospital requisites, veterinary medicines, tinctures, extracts and all other allied or incidental products. 2. To carry on the business of marketing, promotion, distribution and sale of the products of the Company including pharmaceuticals, nutraceuticals, healthcare products, ayurvedic products and allied products through recognized and lawful commercial channels including retail trade, wholesale trade, institutional sales, franchise arrangements, e-commerce platforms, digital marketplaces and such other lawful modes of distribution. The alteration in the Object Clause has been approved by the Members with the objective of providing the Company with a broader and more comprehensive object framework for carrying on and expanding its business activities in the pharmaceutical, healthcare, nutraceutical, ayurvedic and allied sectors. GSTIN NO.: 06AAPCA4446E1ZP I CIN: L24304CH2017PLC041482 (Formely known as Astonea Labs Private Limited) Reg.Off: SCO 321-322, Basement, Sector 35B, Chandigarh, India-160022 Corporate Office: 63, Industrial Area, Phase II, Panchkula, Haryana, India-134113 Plant: Village Haripur, Teh. Raipur Rani, Distt., Panchkula, India-134204 Mobile No.:+91 7888 491 385, Email: info@astonea.org, Website: https://astonea.org/